Form 4: Day One Biopharmaceuticals Executive Adam Dubow Reports Stock Transactions

Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) to cover tax liabilities.

Summary

• On May 15 and 16, 2024, Adam Dubow, General Counsel of Day One Biopharmaceuticals, engaged in transactions involving the company's common stock and Restricted Stock Units (RSUs).
• Dubow acquired shares through the vesting of RSUs and disposed of some shares to cover tax obligations related to the RSU settlements.
• Specifically, on May 15, 2024, Dubow acquired 2,962, 1,750, and 3,687 shares of common stock through RSU conversions.
• On May 16, 2024, Dubow sold 3,253 shares at a price of $16.0787 per share.
• Following these transactions, Dubow directly owns 21,731 shares of common stock and holds derivative securities including 29,626, 17,500, and 51,626 RSUs.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are routine and related to compensation and tax obligations. There is no indication of strategic shifts or concerns about the company's performance.

Positives

• The vesting of RSUs indicates that Dubow is meeting the service requirements of his employment agreement.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests. These filings are a routine part of regulatory compliance for publicly traded companies.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the pharmaceutical industry to gauge executive sentiment and potential future performance.
• Comparing the volume and frequency of insider transactions at Day One Biopharmaceuticals to peers like Relay Therapeutics or Black Diamond Therapeutics can provide insights into relative valuation and management confidence.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The transparency provided by the Form 4 filing ensures that stakeholders are informed about insider transactions.

Key Dates